Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals ) Identifier:
First received: August 19, 2010
Last updated: February 28, 2017
Last verified: February 2017
This blinded extension study is designed to offer patients with relapsing-remitting MS having completed the core study CBAF312A2201 access to BAF312 until they can enter an open label study. It will provide data on long-term safety, tolerability and efficacy of BAF312 in this patient population.

Condition Intervention Phase
Relapsing Remitting Multiple Sclerosis
Autoimmune Diseases
Immune System Diseases
Nervous System Diseases
Autoimmune Diseases of the Nervous System
Drug: BAF312
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Participant, Care Provider, Investigator, Outcomes Assessor
Primary Purpose: Treatment
Official Title: A Dose Blinded Extension Study to the CBAF312A2201 Study to Evaluate Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

Resource links provided by NLM:

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Long-term safety and tolerability (emphasis on cardiovascular events, viral infections, macular edema and dermatologic alterations) [ Time Frame: up to 15 months ]

Secondary Outcome Measures:
  • Long-term efficacy on clinical ground (relapse rate, disability progression) [ Time Frame: up to 15 months ]
  • Long-term efficacy on paraclinical ground (neuroradiological measures of neurodegeneration) [ Time Frame: up to 15 months ]

Enrollment: 185
Study Start Date: August 2010
Study Completion Date: October 2016
Primary Completion Date: October 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BAF312, 10 mg Drug: BAF312
Experimental: BAF312, 2 mg Drug: BAF312
Experimental: BAF312, 0.5 mg Drug: BAF312
Experimental: BAF312, dose between 0.1- 8 mg blinded Drug: BAF312
Experimental: BAF312, dose between 0.1- 8 mg blinded. Drug: BAF312


Ages Eligible for Study:   18 Years to 56 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients completed the core study BAF312A2201
  • Written informed consent provided before any assessment of the extension study
  • Female patients at risk of becoming pregnant must have a negative pregnancy test and use simultaneously two forms of effective contraception

Exclusion Criteria:

  • Newly diagnosed systemic disease other than MS (which may require immunosuppressive treatment)
  • Malignancies, diabetes, significant cardiovascular and pulmonary diseases and conditions
  • Active infections

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01185821

  Show 46 Study Locations
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Novartis Pharmaceuticals Identifier: NCT01185821     History of Changes
Other Study ID Numbers: CBAF312A2201E1
2009-014392-51 ( EudraCT Number )
Study First Received: August 19, 2010
Last Updated: February 28, 2017

Keywords provided by Novartis:
Multiple Sclerosis
Relapsing remitting Multiple Sclerosis
Demyelinating Autoimmune Diseases

Additional relevant MeSH terms:
Multiple Sclerosis
Nervous System Diseases
Autoimmune Diseases
Multiple Sclerosis, Relapsing-Remitting
Immune System Diseases
Autoimmune Diseases of the Nervous System
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Demyelinating Diseases processed this record on May 22, 2017